Protalix BioTherapeutics, Inc. Stock TEL AVIV STOCK EXCHANGE
Stocks
PLX
US74365A3095
Pharmaceuticals
|
Delayed
TEL AVIV STOCK EXCHANGE
19:24:48 21/03/2023 +04
|
5-day change | 1st Jan Change | ||
| 732.50 ILa | -.--% |
|
+3.29% | +69.68% |
| Market Cap | 222M 0 196M 186M 168M 316M 21.32B 320M 2.22B 854M 10.9B 835M 817M 34.95B | P/E 2026 * |
11.5x | P/E 2027 * | 55.2x |
|---|---|---|---|---|---|
| Enterprise Value | 222M 0 196M 186M 168M 316M 21.32B 320M 2.22B 854M 10.9B 835M 817M 34.95B | EV / Sales 2026 * |
2.71x | EV / Sales 2027 * | 3.35x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix BioTherapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 30/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 24/08/2025 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 01/07/2008 |
Aharon Schwartz
BRD | Director/Board Member | 83 | 01/11/2014 |
Dror Bashan
BRD | Director/Board Member | 59 | 30/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +3.29% | - | - | 222M | |
| -2.33% | +0.53% | +51.65% | +115.42% | 1,031B | |
| -1.06% | -1.65% | +42.78% | +69.98% | 638B | |
| -0.65% | -1.32% | +12.98% | +75.49% | 462B | |
| -2.66% | -1.87% | +73.13% | +41.15% | 359B | |
| -0.34% | -4.51% | +22.92% | +39.89% | 335B | |
| -1.39% | -0.79% | +13.46% | +26.40% | 273B | |
| -1.76% | -2.90% | -3.18% | +9.95% | 253B | |
| -0.50% | +3.80% | +49.37% | +56.84% | 228B | |
| -1.47% | -1.53% | +34.28% | +98.89% | 185B | |
| Average | -0.39% | -0.36% | +33.04% | +59.33% | 418.21B | |
| Weighted average by Cap. | -0.23% | -0.35% | +37.44% | +71.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 82.16M 0 72.35M 68.55M 61.88M 117M 7.88B 118M 820M 316M 4.03B 309M 302M 12.91B | 66.48M 0 58.54M 55.47M 50.07M 94.38M 6.37B 95.6M 664M 255M 3.26B 250M 244M 10.45B |
| Net income | 19.63M 0 17.29M 16.38M 14.79M 27.87M 1.88B 28.23M 196M 75.42M 962M 73.72M 72.11M 3.09B | 3.79M 0 3.34M 3.17M 2.86M 5.39M 364M 5.46M 37.87M 14.57M 186M 14.25M 13.94M 596M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PLX Stock
- PLX Stock
Select your edition
All financial news and data tailored to specific country editions
